Lista de obras - Clemens-Martin Wendtner - Dominio Público Uruguay

A novel hierarchical prognostic model of AML solely based on molecular mutations

artículo científico publicado en 2012

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

artículo científico publicado en 2016

B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides

artículo científico publicado en 2012

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

artículo científico publicado en 2016

Basophils go wild when mosquitoes bite CLL.

artículo científico publicado en 2016

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

artículo científico publicado en 2015

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

artículo científico publicado en 2011

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

artículo científico publicado en 2012

CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes

artículo científico publicado en 2007

CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation

artículo científico publicado en 2011

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells

artículo científico publicado en 2016

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

artículo científico publicado en 2013

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells

artículo científico publicado en 2012

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

artículo científico publicado en 2008

Contact investigation for imported case of Middle East respiratory syndrome, Germany

scientific article published on April 2014

Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia

artículo científico

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

artículo científico publicado en 2014

Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction

artículo científico publicado en 2014

Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.

artículo científico publicado en 2002

Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides

artículo científico publicado en 2003

Eradication of minimal residual disease in chronic lymphocytic leukemia

scientific article published on January 2008

Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia

artículo científico publicado en 2012

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

artículo científico publicado en 2016

Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes

artículo científico publicado en 2004

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

artículo científico publicado en 2011

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

artículo científico publicado en 2016

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

artículo científico publicado en 2010

High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors

artículo científico publicado en 2003

Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells

artículo científico publicado en 2006

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

artículo científico publicado en 2017

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

artículo científico publicado en 2015

MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes

artículo científico publicado en 2006

Malignant Peripheral Nerve Sheath Tumor of the Scalp: Case Report and Review of the Literature ⬇️

artículo científico publicado el 26 de julio de 2011

Meningeal spread of blastic plasmacytoid dendritic cell neoplasm

artículo científico publicado en 2014

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

artículo científico publicado en 2015

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

artículo científico publicado en 2010

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

artículo científico publicado en 2010

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update

artículo científico publicado en 2015

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

artículo científico publicado en 2015

Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2014

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

artículo científico publicado en 2014

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

artículo científico publicado en 2013

Subtotal spleen necrosis

artículo científico publicado en 2015

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

artículo científico publicado en 2015

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

artículo científico publicado en 2008

The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature

artículo científico publicado en 2011

There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma ⬇️

artículo científico publicado el 16 de julio de 2013

Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells

artículo científico publicado en 2005

Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy

artículo científico publicado en 2013

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

artículo científico publicado en 2016

What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy

artículo científico publicado en 2016

miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia

artículo científico publicado en 2009

miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.

artículo científico publicado en 2015

Lista de obras de Clemens-Martin Wendtner

A novel hierarchical prognostic model of AML solely based on molecular mutations

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Basophils go wild when mosquitoes bite CLL.

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes

CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells

Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

Contact investigation for imported case of Middle East respiratory syndrome, Germany

Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction

Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.

Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides

Eradication of minimal residual disease in chronic lymphocytic leukemia

Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors

Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes

Malignant Peripheral Nerve Sheath Tumor of the Scalp: Case Report and Review of the Literature ⬇️

Meningeal spread of blastic plasmacytoid dendritic cell neoplasm

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update

Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).

Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Subtotal spleen necrosis

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression

The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes

The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature

There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma ⬇️

Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells

Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy

miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia

miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.